MIBG-131-T
IOBENGUANE (131|)
| Name | IOBENGUANE (131I) injection for therapy |
| Pharmaceutical form | Solution for infusion or for intravenous injection |
| Nuclide | Iodine 131 |
| Half life | 8.02 days |
| Availability | Two first Tuesday of each month |
| Ordering deadline | Thursday 11 a.m. |
| Radioactive concentration | 370 MBq/mL |
| Calibration | Wednesday 12 a.m. |
| Available quantities | 1850 - 3700 and 5550 MBq |
| Maximum activity / vial | 5550 MBq |
| Expiry | 7 days from the manufacturing date, 5 hours after thawing |
| Specific activity | ≥ 400 GBq/g iobenguane at calibration |
| Radiochemical purity | ≥ 92 % |
| Radionuclidic purity | 131I ≥ 99.9 % ; 133I + 135I ≤ 0.1 % at calibration |
| pH and composition | 3.5 - 5.5 in saline acetate buffer |
| Storage | At - 18°C |
| Indication | Radiation therapy of tumour-tissue that is capable of retaining metaiodobenzylguanidine: pheochromocytomas neuroblastomas, carcinoid and medullary carcinomas of the thyroid gland |
Support Solution
IBA does not provide pharmaceuticals... we do much more than that. Beyond the quality of our products and services you expect a leading radiopharmaceutical company to provide you with all the environment necessary to master our products and to operate your daily activity in a professional manner.
Our set of customer solutions includes :
- Product trainings
- Round tables facilitation
- Patient recruitment support
- ISS (Investigator Sponsored Studies)
- Organisations of symposiums
- Newsletters
